These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 19786136)

  • 1. Optimized subunit vaccine protects against experimental leishmaniasis.
    Bertholet S; Goto Y; Carter L; Bhatia A; Howard RF; Carter D; Coler RN; Vedvick TS; Reed SG
    Vaccine; 2009 Nov; 27(50):7036-45. PubMed ID: 19786136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
    Rostamian M; Niknam HM
    Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant.
    Skeiky YA; Coler RN; Brannon M; Stromberg E; Greeson K; Crane RT; Webb JR; Campos-Neto A; Reed SG
    Vaccine; 2002 Sep; 20(27-28):3292-303. PubMed ID: 12213399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.
    Coler RN; Skeiky YA; Bernards K; Greeson K; Carter D; Cornellison CD; Modabber F; Campos-Neto A; Reed SG
    Infect Immun; 2002 Aug; 70(8):4215-25. PubMed ID: 12117930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total Leishmania antigens with Poly(I:C) induce Th1 protective response.
    Sanchez MV; Eliçabe RJ; Di Genaro MS; Germanó MJ; Gea S; García Bustos MF; Salomón MC; Scodeller EA; Cargnelutti DE
    Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28901553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi.
    Gomes R; Teixeira C; Oliveira F; Lawyer PG; Elnaiem DE; Meneses C; Goto Y; Bhatia A; Howard RF; Reed SG; Valenzuela JG; Kamhawi S
    PLoS Negl Trop Dis; 2012; 6(4):e1610. PubMed ID: 22509423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A specific Leishmania infantum polyepitope vaccine triggers Th1-type immune response and protects against experimental visceral leishmaniasis.
    Lopes Valentim Di Paschoale Ostolin T; Rodrigues Gusmão M; Augusto Siqueira Mathias F; Mirelle de Oliveira Cardoso J; Mendes Roatt B; Dian de Oliveira Aguiar-Soares R; Conceição Ruiz J; de Melo Resende D; Cristiane Fortes de Brito R; Barbosa Reis A
    Cell Immunol; 2022 Oct; 380():104592. PubMed ID: 36084402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.
    Hamrouni S; Bras-Gonçalves R; Kidar A; Aoun K; Chamakh-Ayari R; Petitdidier E; Messaoudi Y; Pagniez J; Lemesre JL; Meddeb-Garnaoui A
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008093. PubMed ID: 32176691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice.
    Peters NC; Bertholet S; Lawyer PG; Charmoy M; Romano A; Ribeiro-Gomes FL; Stamper LW; Sacks DL
    J Immunol; 2012 Nov; 189(10):4832-41. PubMed ID: 23045616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.
    Ravindran R; Bhowmick S; Das A; Ali N
    BMC Microbiol; 2010 Jun; 10():181. PubMed ID: 20576102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis.
    Cecílio P; Pérez-Cabezas B; Fernández L; Moreno J; Carrillo E; Requena JM; Fichera E; Reed SG; Coler RN; Kamhawi S; Oliveira F; Valenzuela JG; Gradoni L; Glueck R; Gupta G; Cordeiro-da-Silva A
    PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005951. PubMed ID: 29176865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major.
    Cote-Sierra J; Bredan A; Toldos CM; Stijlemans B; Brys L; Cornelis P; Segovia M; de Baetselier P; Revets H
    Infect Immun; 2002 Jan; 70(1):240-8. PubMed ID: 11748189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells.
    Resende DM; Caetano BC; Dutra MS; Penido ML; Abrantes CF; Verly RM; Resende JM; Piló-Veloso D; Rezende SA; Bruna-Romero O; Fernandes AP; Gazzinelli RT
    Vaccine; 2008 Aug; 26(35):4585-93. PubMed ID: 18588933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells.
    Coler RN; Goto Y; Bogatzki L; Raman V; Reed SG
    Infect Immun; 2007 Sep; 75(9):4648-54. PubMed ID: 17606603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A recombinant fusion protein displaying murine and human MHC class I- and II-specific epitopes protects against Leishmania amazonensis infection.
    Martins VT; Lage DP; Duarte MC; Carvalho AM; Costa LE; Mendes TA; Vale DL; Menezes-Souza D; Roatt BM; Tavares CA; Soto M; Coelho EA
    Cell Immunol; 2017 Mar; 313():32-42. PubMed ID: 28049560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
    Ravindran R; Maji M; Ali N
    Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
    Coelho EA; Tavares CA; Carvalho FA; Chaves KF; Teixeira KN; Rodrigues RC; Charest H; Matlashewski G; Gazzinelli RT; Fernandes AP
    Infect Immun; 2003 Jul; 71(7):3988-94. PubMed ID: 12819086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.
    Rafati S; Gholami E; Hassani N; Ghaemimanesh F; Taslimi Y; Taheri T; Soong L
    Vaccine; 2007 May; 25(21):4159-69. PubMed ID: 17395340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
    Bhowmick S; Ravindran R; Ali N
    Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.